Nicoletta Colombo, MD, PhD

Articles

Endometrial Cancer: Broadening Therapeutic Options in pMMR - Insights from DUO-E/AtTEnd

December 12th 2025

Panelists discuss how DUO-E and AtTEnd broaden options beyond PD-1 approaches, with PD-L1 and PARP–immunotherapy combinations offering promising signals for selected pMMR subgroups amid real-world access and tolerability considerations.

Endometrial Cancer: An Integrated View of LEAP-001, KEYNOTE-775, RUBY and NRG-GY018 for Treatment Strategy

December 12th 2025

Panelists discuss how comparing LEAP-001, KEYNOTE-775, RUBY, and NRG-GY018 helps position lenvatinib plus pembrolizumab mainly after chemotherapy (or when chemo isn’t feasible) while reinforcing chemo–PD-1 combinations—especially in dMMR disease.

Endometrial Cancer: Interpreting dMMR and Post-Adjuvant Activity from LEAP-001

December 5th 2025

Panelists discuss how LEAP-001, despite missing primary endpoints, suggested meaningful activity for lenvatinib plus pembrolizumab in dMMR and post-adjuvant subgroups who may need alternatives to standard frontline chemotherapy.

Endometrial Cancer Today: Defining the Persistent Unmet Needs in Advanced and Recurrent Disease

December 5th 2025

Panelists discuss how advanced/recurrent endometrial cancer has remained a high unmet need due to years of minimal survival gains with carboplatin/paclitaxel until immunotherapy began shifting outcomes.

Dr Colombo on the Rationale for Evaluating Pembrolizumab Plus Paclitaxel With/Without Bevacizumab in PROC

November 4th 2025

Nicoletta Colombo, MD, PhD, discusses the rationale for evaluating pembrolizumab plus weekly paclitaxel with/without bevacizumab in recurrent PROC.

Oncology Experts Dive Into Top Data From ESMO 2025

November 4th 2025

At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.

Dr. Colombo on the Next Steps With Pembrolizumab in Cervical Cancer

October 28th 2021

Nicoletta Colombo, MD, PhD, discusses the next steps with pembrolizumab in cervical cancer.

Dr. Colombo on Practice-Changing KEYNOTE-826 Data in Metastatic Cervical Cancer

October 5th 2021

Nicoletta Colombo, MD, PhD, discusses efficacy achieved with the addition of pembrolizumab to chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer.

The Future of Endometrial Cancer Treatment

June 4th 2021

Experts give insight on what they are looking forward to in the endometrial cancer space.

A Look at Surgical Innovations in EC

June 4th 2021

Nicoletta Colombo, MD, PhD, reviews surgical advancements in endometrial cancer.

Novel Targets of Interest in EC

June 4th 2021

Experts in endometrial cancer comment on novel targets of interest that are currently being investigated.

Insight on Ongoing Trials in EC

June 4th 2021

Key opinion leaders take a look at the evolving treatment landscape in endometrial cancer, discussing ongoing trials in the space.

Incorporating Molecular Features into Choosing Adjuvant Therapy

June 4th 2021

Experts discuss the importance of incorporating molecular features into the selection of adjuvant treatment.

Therapeutic Sequencing in Endometrial Cancer

June 4th 2021

Experts in endometrial cancer comment on therapeutic sequencing in endometrial cancer.

Managing AEs With Pembrolizumab and Lenvatinib

June 1st 2021

Key opinion leaders emphasize the importance of the management of adverse events in using pembrolizumab and lenvatinib.

Experience in Using Pembrolizumab + Lenvatinib in Advanced Endometrial Cancer

June 1st 2021

Experts give insight on their clinical use of pembrolizumab-lenvatinib. They highlight dose adjustments and the importance of the increased knowledge of adverse events.

A Discussion on the Study 309/KEYNOTE-775 Data

May 25th 2021

Key opinion leaders discuss the presented data from Study 309/KEYNOTE-775, highlighting patient reported outcomes, safety, and dosing.

Results from Study 309/KEYNOTE-775

May 25th 2021

Vicky Makker, MD, presents the results from Study 309/KEYNOTE-775, as well as key safety findings.

Study 309/KEYNOTE-775 Trial Design

May 18th 2021

Vicky Makker, MD, walks through the trial design of Study 309/KEYNOTE-775.

Therapeutic Approaches in Endometrial Cancer

May 18th 2021

Experts review optimal approaches to treatment in advanced endometrial cancer, touching on clinical trial data.